Advertisement

Document › Details
PureTech Health plc. (2/24/17). "Press Release: PureTech Health to Present at the Cowen and Company 37th Annual Health Care Conference". Boston, MA.
![]() |
Region | Boston, MA |
Country | United States (USA) | |
![]() |
Organisation | PureTech Health plc (LSE: PRTC) |
Group | PureTech Health (Group) | |
Organisation 2 | Cowen & Company LLC | |
Group | Cowen (Group) | |
![]() |
Product | Cowen & Co. Annual Health Care Conference 2017 Boston |
Product 2 | biopharmaceutical | |
![]() |
Index term | PureTech Health–Cowen: investor conference, 201703 supply service PureTech Health presents at Cowen & Co Annual Health Care Conference 2017 |
![]() |
Person | Zohar, Daphne (PureTech Health 2016 CEO + Co-Founder) |
PureTech Health plc (LSE: PRTC), a cross-disciplinary biopharmaceutical company, today announced that Daphne Zohar, PureTech Health’s Chief Executive Officer, will present at the Cowen and Company 37th Annual Health Care Conference on Monday, 6 March, at 3:20pm EST.
A webcast of the presentation will be available at http://puretechhealth.com/investors.php under the Reports and Presentations tab.
About PureTech Health
PureTech Health (PureTech Health plc, PRTC.L) is a cross-disciplinary biopharmaceutical company creating 21st century medicines that modulate the adaptive human systems. Our therapies target the immune, nervous, and gastro-intestinal systems by addressing the underlying pathophysiology of disease from a systems perspective rather than through a single receptor or pathway. We have multiple human proof-of-concept studies and pivotal or registration studies expected to read out in the next two years. PureTech Health’s rich and growing research and development pipeline has been developed in collaboration with some of the world’s leading scientific experts who, along with PureTech's experienced team and board, analyze more than 650 scientific discoveries per year to identify and advance only the opportunities we believe hold the most promise for patients. This team and process place PureTech Health on the cutting edge of ground-breaking science and technological innovation and leads the Company between and beyond existing disciplines. For more information, visit www.puretechhealth.com or connect with us on Twitter.
Forward Looking Statement
This press release contains statements that are or may be forward-looking statements, including statements that relate to the company's future prospects, developments and strategies. The forward-looking statements are based on current expectations and are subject to known and unknown risks and uncertainties that could cause actual results, performance and achievements to differ materially from current expectations, including, but not limited to, those risks and uncertainties described in the risk factors included in the regulatory filings for PureTech Health plc. These forward-looking statements are based on assumptions regarding the present and future business strategies of the company and the environment in which it will operate in the future. Each forward-looking statement speaks only as at the date of this press release. Except as required by law and regulatory requirements, neither the company nor any other party intends to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.
Contacts
PureTech Health
Media:
Allison Mead, +1 617-651-3156
amead@puretechhealth.com
or
Investors:
Graham Morrell, +1 617-986-1659
gm@puretechhealth.com
Record changed: 2023-06-05 |
Advertisement

More documents for PureTech Health (Group)
- [1] Gilde Healthcare Partners. (6/2/21). "Press Release: Gilde Healthcare Appoints Joep Muijrers to Lead Investments in Public Markets". Utrecht....
- [2] PureTech Health plc. (1/23/20). "Press Release: PureTech Receives $200 Million from Sale of a Minority Portion of Affiliate Shares"....
- [3] PureTech Health plc. (4/17/19). "Press Release: PureTech Health Announces Collaboration with Boehringer Ingelheim to Advance Immuno-oncology Product Candidates Using Its Lymphatic Targeting Platform". Boston, MA....
- [4] Karuna Pharmaceuticals, Inc.. (8/2/18). "Press Release: Karuna Completes $42 Million Series A Financing Round to Advance Selective Muscarinic Receptor Agonist Program into Phase 2 Study". Boston, MA....
- [5] PureTech Health plc. (4/24/18). "Press Release: PureTech Health Appoints Joep Muijrers as Chief Financial Officer"....
- [6] PureTech Health plc. (3/24/17). "Press Release: PureTech Health Announces Licensing and Equity Agreement with Novartis to Advance Clinical Stage mTORC1 Programs". Boston, MA....
- [7] PureTech Health plc. (3/2/17). "Press Release: PureTech Health Appoints Bharatt Chowrira, Ph.D., J.D., as President and Chief of Business and Strategy". Boston, MA....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement

» top